

ChemoCentryx

*Fourth Quarter and Full Year 2016
Financial Results Conference Call*

March 14, 2017



Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “contemplate,” “believe,” “estimate,” “predict,” “project,” “seek,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described more fully in our periodic reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 14, 2017, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. The forward-looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.



CCXI Late Stage: Kidney Disease Franchise

THERAPEUTIC AREA DRUG INDICATION (TARGET) PRECLINICAL PHASE I PHASE II PHASE III

Complement Inhibition in Orphan and Rare Diseases

Avacopan (formerly CCX168)

ANCA ASSOCIATED VASCULITIS (C5aR)

ATYPICAL HEMOLYTIC UREMIC SYNDROME (C5aR)

C3 GLOMERULOPATHY (C5aR)

Chronic and Other Rare Kidney Diseases


CCX140

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (CCR2)

DIABETIC NEPHROPATHY (CCR2)



CCXI Retains Commercial Rights in U.S.



CCXI Early Stage Drug Candidates

THERAPEUTIC AREA	DRUG	INDICATION (TARGET)	PRECLINICAL	PHASE I	PHASE II	PHASE III
------------------	------	---------------------	-------------	---------	----------	-----------

Immuno-Oncology	CCX872	ADVANCED PANCREATIC CANCER (CCR2)				
		OTHER ONCOLOGY TARGETS (CCR1, CXCR2)				

**Other
Inflammatory and
Autoimmune
Diseases**

Vercirnon*	INFLAMMATORY BOWEL DISEASE (IBD): CROHN'S DISEASE (CCR9)				
	CCX507	IBD: ULCERATIVE COLITIS (CCR9)			
	CCX991	PSORIASIS AND TH17 DISEASES (CCR6)			

CCX140: DIABETIC NEPHROPATHY; FSGS (CCR2)

* Also known as CCX282 or Traficet-EN.



Q4 and Full Year 2016 Financial Results

- Proforma cash and investments - \$194 million
- Total shares outstanding – 48.1 million
- Consolidated statement of operations -

	Three Months Ended		Twelve Months Ended	
	December 31,		December 31,	
	2016	2015	2016	2015
Consolidated Statement of Operations				
Revenue:				
Collaboration and license revenue	\$ 4,684	\$ -	\$ 11,435	\$ -
Grant revenue	205	-	500	-
Total revenue	4,889	-	11,935	-
Operating expenses:				
Research and development	9,249	8,230	37,945	33,183
General and administrative	3,556	3,430	14,710	14,506
Total operating expenses	12,805	11,660	52,655	47,689
Loss from operations	(7,916)	(11,660)	(40,720)	(47,689)
Interest income	251	86	757	384
Net loss	\$ (7,665)	\$ (11,574)	\$ (39,963)	\$ (47,305)

